Related Experiment Videos
New directions for ZD1839 in the treatment of solid tumors
1Section of Medical Oncology, Department of Medicine, University of Wisconsin Medical School, Comprehensive Cancer Center, Madison, WI 53792-6164, USA.
Abstract:
Among molecular mechanisms of tumor growth and progression, activated epidermal growth factor receptor-tyrosine kinase is remarkable for its prevalence and impact on many different solid tumor types, as well as its link to diverse stages of disease. ZD1839, (Iressa; AstraZeneca Pharmaceuticals LP, Wilmington, DE) an oral epidermal growth factor receptor-tyrosine kinase inhibitor, is also being explored for its potential in the treatment of other common solid tumors, including breast cancer, colorectal cancer, and hormone-refractory prostate cancer. Clinical trials include studies of ZD1839 as monotherapy and in combination with various chemotherapy, radiation, and hormone therapy regimens. ZD1839 is also being studied in conjunction with other targeted therapies, such as trastuzumab. In addition to advanced and refractory disease, ZD1839 may also be applicable for use in earlier stage cancers. Chemoprevention trials have been initiated to assess the potential of ZD1839 to delay or prevent the progression of common solid tumors such as non-small cell lung cancer.
Insights
ZD1839, an epidermal growth factor receptor-tyrosine kinase inhibitor, shows promise in treating various solid tumors. Clinical trials are evaluating its efficacy as monotherapy and in combination treatments for advanced and early-stage cancers.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Activated epidermal growth factor receptor-tyrosine kinase (EGFR-TK) is a key driver in many solid tumors.
- EGFR-TK activation is implicated in tumor growth, progression, and diverse disease stages.
Purpose of the Study:
- To explore the therapeutic potential of ZD1839 (Iressa), an oral EGFR-TK inhibitor.
- To investigate ZD1839's efficacy in various solid tumors, including breast, colorectal, and prostate cancers.
- To assess ZD1839's role in combination therapies and chemoprevention strategies.
Main Methods:
- Clinical trials evaluating ZD1839 as monotherapy.
- Studies combining ZD1839 with chemotherapy, radiation, and hormone therapy.
- Investigating ZD1839 in conjunction with other targeted therapies like trastuzumab.
- Initiation of chemoprevention trials for early-stage cancers, including non-small cell lung cancer.
Main Results:
- ZD1839 demonstrates potential in treating advanced and refractory solid tumors.
- Ongoing trials explore its application in earlier stages of cancer.
- Combination therapies with ZD1839 are under investigation for enhanced efficacy.
- Chemoprevention studies aim to assess its role in delaying tumor progression.
Conclusions:
- ZD1839 is a promising EGFR-TK inhibitor with broad applicability across solid tumor types and stages.
- Further clinical investigation is warranted to establish its role in cancer treatment and prevention.
- Targeted inhibition of EGFR-TK represents a significant therapeutic strategy in oncology.